Update shared on05 Sep 2025
Analysts cite improving membership trends, positive pre-announcements, and strategic partnerships expanding Progyny's women's health services as driving renewed confidence and modest upgrades, though the consensus price target remains unchanged at $28.25.
Analyst Commentary
- Bullish analysts cite a rebound in membership activity, highlighted by two consecutive positive pre-announcements, as signaling recovery from last year's lows and renewed momentum.
- Increased comfort with improving membership trends has led to more constructive stances, with some upgrades to Outperform ratings.
- The addition of pelvic floor therapy and partnerships with Hinge Health and Origin are seen as expanding Progyny's women's health solutions and broadening its network.
- Strategic partnerships are expected to drive yield expansion and generate positive initial feedback in new health program launches.
- JPMorgan's modest price target increase reflects updated company modeling, accounting for recent business developments.
What's in the News
- Progyny raised full-year 2025 earnings guidance, projecting revenue of $1.235–$1.270 billion (excluding a major transitioning client, core revenue growth is expected at 15.1–18.5%) and net income of $52.3–$58.9 million, or $0.58–$0.65 per diluted share.
- Issued third-quarter 2025 guidance with revenue projected at $290–$305 million, and net income at $9.4–$12.3 million, or $0.10–$0.14 per diluted share.
- Announced a partnership with OURA to offer wearable health insights and data integration for women’s health, available to clients beginning in early 2026.
- Added pelvic floor therapy (in-person and digital) to its women’s health solutions portfolio through expanded provider network and collaboration with Hinge Health.
- Established a new collaboration with Amazon’s Health Benefits Connector to expand access and streamline enrollment in Progyny's comprehensive women’s health services.
Valuation Changes
Summary of Valuation Changes for Progyny
- The Consensus Analyst Price Target remained effectively unchanged, at $28.25.
- The Net Profit Margin for Progyny remained effectively unchanged, at 7.04%.
- The Future P/E for Progyny remained effectively unchanged, at 26.82x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.